NCT06112691|Unknown
ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY IN THE CHERNIVTSI REGION (Pilot Study)
AIMDR
USING ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY
Loading search results
AIMDR
USING ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY
Sponsor study identifier
observational
660
1 country
1
Study Start
February 1, 2022
Actual (reported)Primary Completion
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to create a patient-centric environment for early detection of DR with AI-driven solutions.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2022
Actual (reported)October 29, 2023
Actual (reported)November 1, 2023
Actual (reported)October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The accuracy
The accuracy of detecting of DR
Baseline-Month 12
The percent of invalid images
Baseline-Month 12
The percent of false positive detection of DR
Baseline-Month 12
diabetes mellitus
without diagnosis of diabetes mellitus without retinal diseases
using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
660 participants were planed to include in study, 410 of them had diabetes mellitus and 250 participants were as a control group without diagnosis of diabetes mellitus. All participants were selected for the study based on the following inclusion and exclusion criteria
The Filatov Institute of Eye Diseases and Tissue Therapy
Odesa, 65061, Ukraine
Andrii MD Korol, PhD
The Filatov Institute of Eye Diseases and Tissue Therapy
First Submitted
October 29, 2023
First Posted
November 1, 2023
Study Start
February 1, 2022
Actual (reported)Primary Completion
October 2024
Estimated (date passed)Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 1, 2023
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: